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Tourette Syndrome (TS) is a childhood-onset neur-
ological disorder characterised by multiple motor tics
and one or more phonic tics. Number, frequency and
tic complexity vary over time. Although clinical and
epidemiological studies indicate that TS is a partially
inherited disorder, its pathogenesis remains poorly un-
derstood (Singer, 2005). One of the main features of TS
is that its prevalence in children is significantly higher
than in adults; in most TS patients, tic severity follows
a characteristic time course, with onset at 5–7 years of
age, followed by an increase in frequency and intens-
ity until the age 10 and 12 years, and a later remission
phase after puberty (Leckman et al., 1998).
Several clinical studies have highlighted male sex and
environmental stress as risk factors in TS pathogenesis.
TS has a strong male predominance, with a male:female
ratio estimated at 4:1; furthermore, the severity of tics
and accompanying symptoms (such as perceptual altera-
tions, anxiety and obsessive-compulsive behaviours) are
typically exacerbated by environmental stress (Cohen,
Leckman & Bloch, 2013). In consideration of the role
of steroids in the regulation of sex differences and stress
response, these premises suggest that these molecules
may be implicated in the etiology and pathophysiology
of TS. In particular, our research focuses on neuroster-
oids, a family of steroids synthesized by the brain. A
schematic diagram of steroidogenesis is presented in Fig.
1.
The key rate-limiting enzyme in androgens and neur-
osteroids synthesis, 5-alpha reductase (5AR), catalyses
the saturation of the 4,5 double bond of the A ring
of ∆4-3-ketosteroid substrates, such as deoxycorticost-
erone, progesterone, androstenedione and testosterone.
Through this irreversible reaction, ∆4-3-ketosteroid sub-
strates are converted into their pregnane and androstane
Figure 1: Simplified pathway of neurosteroidogenesis. 3-αHSD,
3-alpha hydroxysteroid dehydrogenase; P450-C17, steroid 17
alpha-hydroxylase/17,20 lyase; 17-β-HSD, 17-beta-hydroxysteroid
dehydrogenase (modified from Paba et al., 2011).
metabolites. The physiological importance of 5AR
in the brain derives from its capability to convert
testosterone to the more potent brain active androgen
dihydrotestosterone (DHT), and to convert progester-
one and deoxycorticosterone to their respective 5alpha-
reduced metabolites. These are precursors of allopreg-
nanolone and tetrahydrodeoxycorticosterone, two neur-
osteroids directly implicated in the regulation of stress
response through the positive modulation of the γ-
amino-butyric acid (GABA)A receptor and HPA axis
in response to stress. Among the five types of 5AR
enzymes characterised to date, the first two isoforms
(5AR1 and 5AR2) play major roles in brain steroido-
genesis. The two isoforms are differently expressed and
regulated: 5AR1 is the only isoform present in the glial
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cells; the expression of 5AR2 is under the positive con-
trol of testosterone and DHT, while the expression of
5AR1 is negatively regulated by the same androgens.
Over the years, our group has demonstrated that the
pharmacological inhibition of 5AR elicits therapeutic ef-
fects in animal models of TS (Bortolato et al., 2013). In
particular, we found that the 5AR inhibitors finasteride
and dutasteride normalised the disruption of sensorimo-
tor gating, induced by the non-selective DAergic agon-
ists amphetamine and apomorphine (Bortolato et al.,
2008). Gating deficits, as measured by the paradigm of
prepulse inhibition (PPI) of the acoustic startle reflex,
have been shown to be highly relevant to the sensory
dysregulation described in TS. In fact, PPI deficits are
exhibited by TS patients, and are posited to indicate
the impaired ability to filter out irrelevant stimuli. Al-
though the primary symptoms of TS are motor and vo-
cal tics, several researchers have pointed out the role of
sensory phenomena in the pathogenesis of tics. Sensory
experiences affect tics and, in turn, tics are generated in
response to intrusive sensory phenomena.
The most commonly prescribed drugs for TS are
primarily dopamine antagonists, such as neuroleptics
(e.g. haloperidol), benzamides (e.g. sulpiride) or atyp-
ical antipsychotics (e.g. risperidone). While finasteride
exhibited robust anti-dopaminergic mechanisms similar
to those elicited by haloperidol across several behavi-
oral tasks, its effects were not supported by a direct
antagonism of dopamine receptors. Accordingly, unlike
dopaminergic antagonists, finasteride failed to induce
extrapyramidal side-effects. These latter findings are
in line with our subsequent studies, in which we ana-
lyzed the neurobiological bases of the antipsychotic-like
mechanisms of finasteride. We found that the effects of
systemic finasteride are mediated by a negative mod-
ulation of D1 (but not D2) receptors in both rats and
mice (Frau et al., 2016, 2013). Specifically, the systemic
finasteride administration reverted the PPI deficits pro-
duced by the selective D1 agonist SKF-82958 in Long
Evans and C57BL/J mice, rat and mice strains, with
higher sensitivity to the effects of dopamine D1 receptor
activation. Furthermore, the fact that finasteride did
not counteract the behavioural alterations mediated by
the D2 agonists sumanirole and quinpirole, justifies the
lack of catalepsy in both species, even at the higher dose
tested.
Our results are particularly relevant in view of recent
evidence supporting the therapeutic efficacy of D1 re-
ceptor antagonists in TS. Indeed, by a multicenter, non-
randomized, open-label study, Gilbert and co-workers
(2014) suggest the pharmacologic antagonism of dopam-
ine D1 receptors as a novel approach to tic reduction
in TS. They found a significant reduction in tic sever-
ity, with the selective D1 antagonist ecopipam and a
double-blind trial is ongoing to confirm the efficacy of
this pharmacological approach.
Prompted by these preclinical results, we studied the
therapeutic potential of finasteride in adult male TS pa-
tients. Of note, finasteride, at the same dose used for the
treatment of benign prostatic hyperplasia (5 mg/day),
led to a gradual improvement of motor and vocal tics
in TS patients, as assessed by the Yale Tic Severity
Scale, with no reported side effects. Furthermore, the
discontinuation of the chronic treatment resulted in an
abrupt, dramatic exacerbation of the symptoms, which
was countered by the reinstatement of the 5AR inhib-
itor (Bortolato, Muroni & Marrosu, 2007). Importantly,
these preliminary findings have been confirmed in a fol-
lowing open-label study, in which adult male patients
show a significant decrease of severity of tics by the sixth
week of therapy, with a plateau in the therapeutic effects
by the 12th week of finasteride administration. Notably,
as in rodents, finasteride did not elicit extrapyramidal
side effects in patients (Muroni, Paba, Puligheddu, Mar-
rosu & Bortolato, 2011).
Our preclinical and clinical findings clearly indicated
that 5AR plays a key role in the pathophysiology of TS,
through the modulation of DA neurotransmission and
signalling. In addition, recent preclinical results from
our group have suggested that other steroidogenic en-
zymes might be involved in the pathogenesis of TS. Ac-
cordingly, the systemic and intracerebral injections of
abiraterone, inhibitor of CYP450 C17, the alternative
enzyme responsible of androgens formation, show be-
neficial effects in animal model of TS, further pointing
to the implication of androgen synthesis in TS patho-
genesis (Frau et al., 2014). The findings that abirater-
one and finasteride elicit similar effects is of particular
interest, in view of the convergent neurosteroidogenic
pathways and consequent similar substrate and product
steroids, and of the translational potential of our results
for the clinical practice. Furthermore, it is worth noting
that, as reported in TS, the peak age of onset of schizo-
phrenia in males is concomitant with highest testoster-
one levels at adolescence. In addition, studies in the ad-
olescent striatum and substantia nigra of male rats have
shown that testosterone led to increases of tyrosine hy-
droxylase, D1-, D2-, D5-receptor mRNA and dopamine
transporter protein. These data, combined with our pre-
vious findings, suggests that the dopaminergic system is
upon direct influence of androgen signaling throughout
the pubertal/peripubertal period in brain areas with rel-
evance to neurological and neuropsychiatric disorders,
including TS and Schizophrenia (Purves-Tyson et al.,
2012, 2014). Thus, it is not surprising that imbalances
of androgen- or other neurosteroid signaling, specifically
during a critical window of brain development, might
affect the dopaminergic system. As mentioned above,
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a genetic contribution in the etiology of TS has been
consistently shown. Although the data from our and
other group do not lead to drawn conclusions regarding
the functional outcomes, it is feasible that in individuals
with an underlying susceptibility for TS, the increase in
circulating testosterone at adolescence may serve as trig-
ger for the presentation of dopamine-related tic disorder.
In this view, since its role in androgen and neurosteroid
synthesis, 5AR may provide a unique biological target
in those diseases with male predominance and particu-
lar sensitivity to the effects of stress contingencies, in
which TS perfectly matches.
Although finasteride is typically well-tolerated, the
clinical applications of this drug on TS therapy remain
limited; in fact, finasteride cannot be prescribed in chil-
dren, who represent the broadest target population in
this disorder. In addition, finasteride can induce endur-
ing psychoendocrinological side effects in a small sub-
set of patients, including depression and reduction of
libido (Traish, Melcangi, Bortolato, Garcia-Segura &
Zitzmann, 2015). For these reasons, the identification
of the neurobiological bases and molecular mechanisms
underlying the effects of finasteride and other 5AR in-
hibitors, is crucial to overcome their limitations, and
develop novel potential therapeutic tools for TS, with
limited endocrine side effects.
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